ADVENTRX to Participate at the RBC Capital Markets Healthcare Conference
December 07 2006 - 6:18AM
PR Newswire (US)
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing low development risk
pharmaceuticals, announced today that Evan M. Levine, chief
executive officer, was selected to participate in a panel entitled
"New Therapies in Oncology" at the RBC Capital Markets Healthcare
Conference at the Westin New York at Times Square in New York, New
York on Wednesday, December 13th at 2:30 p.m. Eastern time. Michael
Yee, an associate analyst with RBC Capital Markets, will lead the
discussion. A live Web cast of the discussion will be available and
can be accessed via the "Investors" section of the Company's
corporate Web site at http://www.adventrx.com/ under "Events."
After the live Web cast, the discussion will remain available on
the Company's Web site for 14 days. About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing low development risk
pharmaceuticals for cancer and infectious disease that enhance the
efficacy and/or safety of existing therapies. The Company's lead
product candidate, ANX-510 or CoFactor (fotrexorin calcium),
currently is in a phase III clinical trial. More information can be
found on the Company's corporate web site at
http://www.adventrx.com/. Forward-Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors that, if they do not materialize or prove to be accurate,
could cause ADVENTRX's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties that could cause
actual results to differ materially include, but are not limited
to: uncertainties inherent in the drug development process; the
timing and success of clinical trials; the validity of research
results; the receipt of necessary approvals from the FDA and other
regulatory agencies; and other risks and uncertainties more fully
described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with
the Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866
Web site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024